Arrowhead's Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript)

Arrowhead Research Corporation (ARWR)

Wedbush PacGrow Life Sciences Management Access Conference Call

August 14, 2012 4:15 pm ET

Executives

Christopher Anzalone – President and Chief Executive Officer

Analysts

Presentation



Unidentified Analyst

Compare to:
Previous Statements by ARWR
» Arrowhead Research Corporation's CEO Discusses F3Q12 Results - Earnings Call Transcript
» Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript)
» Arrowhead Research CEO Discusses F4Q2010 Results – Earnings Call Transcript

So, we’re pleased to have Arrowhead Research here presenting at the Wedbush Life Sciences Management Access Conference. And let’s presenting for Arrowhead our Research Corporation, which is a public traded company focused on metabolic diseases or obesity another issues is Christopher Anzalone, CEO.

Christopher Anzalone

Thanks very much. All right, so Arrowhead is a targeted therapeutics company and we are focused entirely on gaining drugs, where they can be effective AnginaRex towards, those ends we have developed a number of platforms they enable us to target and to deliver multiple therapeutic mortalities. So we saw – we view these platforms in two primary asylums. One is we have the world largest human right peptide targeting library. This was developed at MD Anderson Cancer Center and we will talk about this in the next couple of slides.

We use these to conjugate the drugs to make peptide-drug conjugates or PDCs. Think of these as next generation antibody-drug conjugate or ADC. We also have extremely broad set of RNAi platforms. This was centered around delivery, but we also have broad premium to operate within RNAi chemistries.

These technologies came from a number of different areas primarily through the acquisition of Roche’s RNAi business back in October of 2011. We have a portfolio of delivery systems and however, we have two primary systems both of which are targetable, they are non-lipid. And so with those we can make targeted RNAi therapeutics. Now we can use those also in conjunction with our peptide library to make targeted – to which make peptide targeted RNAi therapeutics.

1 2 3 Next › Last »